Interpace Biosciences Q4 revenue $8.3M (-9% YoY); FY revenue $31.8M (-4%); loss narrows

INTERPACE BIOSCIENCES, INC.

Q4 net revenue $8.3M, down 9% from $9.1M; operating income $0.1M vs loss of $1.4M prior year.
Full year net revenue $31.8M, down 4% due to ThyGeNEXT reimbursement decline ($3.6M impact).
Full year loss from continuing ops improved to $(5.9)M from $(7.0)M; adjusted EBITDA $(1.2)M vs $(2.0)M.
Cash balance $4.8M at Dec 31, 2022, up from $2.9M at Dec 31, 2021.
Management cites expense reductions and volume growth partially offsetting price headwinds.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INTERPACE BIOSCIENCES, INC. reported the fiscal year ended December 31, 2022 results: revenue $31.8 million.

Period: the fiscal year ended December 31, 2022
Revenue: $31.8 million
Result: reported results

Exact text from the filing

Net Revenue was $31.8 million for 2022, a 4% decrease over the prior year period.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INTERPACE BIOSCIENCES, INC. reported the fourth quarter ended December 31, 2022 results: revenue $8.3 million.

Period: the fourth quarter ended December 31, 2022
Revenue: $8.3 million
Result: reported results

Exact text from the filing

Net Revenue was $8.3 million, a decrease of 9% from $9.1 million for the prior year quarter.

View on SEC.gov

Browse all earnings releases →

INTERPACE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-009109

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.